United-Guardian, Inc. — 2022 Form 10-K
Business context and reporting period
For the fiscal year ended December 31, 2022, United-Guardian manufactured and marketed cosmetic ingredients, pharmaceuticals, medical lubricants, and specialty industrial products. It operates as one business segment. Its two principal product lines, Lubrajel and Renacidin, represented approximately 92% of sales. The filing compares 2022 with 2021.
Key financial metrics
| Metric | 2022 | 2021 |
|---|---|---|
| Net sales | $12.70 million | $13.93 million |
| Gross margin | 53% | 59% |
| Income from operations | $4.04 million | $5.67 million |
| Net income | $2.57 million | $4.66 million |
| Basic and diluted EPS | $0.56 | $1.01 |
| Cash from operating activities | $2.53 million | $5.31 million |
| Cash and cash equivalents at year-end | $0.83 million | $0.53 million |
| Marketable securities at year-end | $5.65 million | $7.64 million |
| Working capital at year-end | $8.60 million | $9.25 million |
| Current ratio | 7.3:1 | 5.0:1 |
Gross profit dollars were approximately $6.70 million in 2022 versus $8.18 million in 2021. The filing reports no interest-bearing debt line or borrowing balance on the balance sheet; no debt amount is otherwise specified. Dividends paid were $0.68 per share in 2022, down from $1.13 in 2021.
Material changes versus 2021
- Sales declined approximately 9%. Cosmetic ingredient sales fell 25% to $5.17 million, primarily due to lower ASI purchases, customer inventory overstocking, and weaker demand in China.
- Pharmaceutical net sales increased approximately 4% to $4.94 million; medical lubricant sales increased 14% to $2.47 million. Industrial and other sales were $0.12 million.
- Gross margin fell from 59% to 53%, reflecting a less favorable sales mix, higher raw-material and shipping costs, a $206,621 rebate payable to a marketing partner, and a one-time employee retention credit that had reduced 2021 costs.
- Operating expenses rose approximately 7% to $2.17 million. Net income declined approximately 45%, also affected by a $1.05 million net loss on marketable securities versus a $23,018 loss in 2021. The 2022 securities loss included $364,074 of realized losses and $682,171 of unrealized losses.
- Operating cash flow decreased to $2.53 million, primarily due to lower net income and declines in accounts payable, accrued expenses, and deferred revenue. Cash provided by investing activities was $0.90 million, while financing cash outflows were $3.12 million, principally dividends.
- Liquidity remained substantial, although working capital declined; the current ratio increased because current liabilities fell more sharply than current assets. Accounts receivable decreased to $1.43 million, while days sales outstanding rose to 47 from 42.
Outlook, risks, contingencies, and unusual items
- Management expects operating expenses to remain relatively consistent in 2023 and R&D spending to be higher than 2022 to support product development. It did not provide revenue or earnings guidance.
- The company expects approximately $100,000 of spending in the first half of 2023 for a building sprinkler-system upgrade. Management said working capital should support the next fiscal year’s operating needs.
- Management plans to discontinue manufacturing and sales of specialty industrial products in the second quarter of 2023, citing their small contribution—less than 2% of sales—and small production scale. Deselex had already been discontinued in March 2022.
- Management identified continuing uncertainty from pandemic effects, supply-chain instability, inflation, higher raw-material, shipping and labor costs, and weaker China demand. Price increases had been instituted on many products. A strong U.S. dollar also made products less competitive in foreign markets.
- Customer and supplier concentration is material: four pharmaceutical wholesalers and cosmetic ingredient distributors accounted for about 72% of gross sales and 81% of year-end receivables in 2022. Six major raw-material vendors represented about 90% of raw-material purchases.
- ASI is the largest cosmetic-ingredient distributor; sales to ASI were approximately 32% of total sales in 2022, down from 42% in 2021. The ASI marketing agreement was scheduled to run through December 31, 2023, with renewal terms described in the filing.
- The company reported no material legal proceedings and no off-balance-sheet transactions. The auditor issued an unqualified opinion and reported no critical audit matters. Management concluded internal controls were effective; the auditor did not provide an internal-control attestation.
Important facts for investors to verify
- Whether cosmetic ingredient demand, particularly in China, and ASI-related sales recover, and how distributor concentration affects results.
- Whether product pricing offsets continuing material, shipping, and labor inflation without further impairing demand or margins.
- The composition and future performance of marketable securities, including the impact of interest-rate changes and realized or unrealized losses.
- Whether pharmaceutical rebates, returns, and related estimates change materially; the year-end reserve for outdated product returns was $369,154.
- Execution and financial effects of the planned industrial-product exit, higher R&D spending, and the sprinkler-system upgrade.
- The filing presents detailed audited annual statements; it does not provide separate fourth-quarter financial results in the supplied text.